1. Home
  2. AEC vs IMMP Comparison

AEC vs IMMP Comparison

Compare AEC & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anfield Energy Inc.

AEC

Anfield Energy Inc.

HOLD

Current Price

$4.76

Market Cap

72.8M

Sector

Real Estate

ML Signal

HOLD

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$0.38

Market Cap

61.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEC
IMMP
Founded
1989
1987
Country
Canada
Australia
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.8M
61.4M
IPO Year
2011
2012

Fundamental Metrics

Financial Performance
Metric
AEC
IMMP
Price
$4.76
$0.38
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$5.50
AVG Volume (30 Days)
42.6K
118.5K
Earning Date
05-01-2015
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$445.09
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.66
$0.29
52 Week High
$12.49
$3.53

Technical Indicators

Market Signals
Indicator
AEC
IMMP
Relative Strength Index (RSI) 52.56 44.18
Support Level $4.04 $0.35
Resistance Level $5.11 $0.39
Average True Range (ATR) 0.27 0.02
MACD 0.03 0.00
Stochastic Oscillator 58.05 22.97

Price Performance

Historical Comparison
AEC
IMMP

About AEC Anfield Energy Inc.

Anfield Energy Inc is a mineral exploration and development company. This company focuses on uranium and vanadium development and near-term production. The exploration project of the company includes Shootaring Canyon Mill and Velvet-Wood and Slick Rock Uranium Project from Uranium One and The West Slope Project located in Montrose and San Miguel Counties in southwestern Colorado. The company's geographical segments are Canada and the United States.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: